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The promising antineoplastic agent diaziquone is asso-
ciated with prolonged aplasia and rare instances of bone
marrow necrosis. but only mild extramedullary toxicity. To
explore the drug’s potential as a myeloablative agent prior
to bone marrow transplantation. we compared its effects
on hematopoietic versus marrow stromal cells. After
short-term (one to six hours) or prolonged (three to seven
days) exposure to the drug. marrow was assayed for
hematopoietic (CFU-Mix, BFU-E. CFU-GM) and stromal
(CFU-F) colony-forming cells and studied in long-term mar-
row culture (LTMC). One- and three-hour treatments pro-
duced little cytotoxicity, even at 5000 ng/mL. After six-
hour treatments with this dose, marrow was depleted of
CFU-Mix, BFU-E, and CFU-GM, but produced CFU-GM in
LTMCs, indicating an ongoing input of CFU-GM from a
surviving pre-CFU--Mix population. In contrast, elimination
of the latter may be inferred from the absence of CFU-GM
in LTMCs exposed for three to seven days to diaziquone at
D IAZIQUONE (AZQ, NSC 182986) is a lipophilic
quinone that was rationally synthesized to optimize
blood-brain barrier penetration.’ Its antineoplastic effect26
has been attributed to alkylating activity.7 Its slow uptake by
leukemic cells8 but short plasma half-Iife”3’9’ led to phase
I/Il trials of prolonged infusions.6 Pancytopenia, not extra-
medullary toxicity, was the dose-limiting factor. This obser-
vation suggested that diaziquone may be best exploited in the
context of bone marrow transplantation. Bone marrow
necrosis, however, occurred in two of three patients given
maximal doses, raising concern that diaziquone may damage
the hematopoietic microenvironment and thereby jeopardize
engraftment.’2 We investigated this issue by using clonal
assays and long term marrow cultures (LTMCs) to correlate
the drug’s ablative capacity on hemopoietic cells with its
effects on marrow stromal cells. Our studies underscore the
usefulness of LTMCs for investigating drug effects on hema-
topoietic and nonhematopoietic components of marrow,
demonstrate that diaziquone’s cellular kinetics render
LTMCs particularly appropriate for defining the effects on
human marrow of prolonged exposure to this drug, and
support the pretransplant use ofdiaziquone in myeloablative
doses.
only 1 50 ng/mL. Under these conditions. CFU-F recovery
was 40% and adherent stromal layers in LTMCs were
similar to untreated controls regarding rate of develop-
ment and cellular composition. Our in vitro pre-CFU-
Mix-ablative regimen correlates with clinical data that
show prolonged but reversible myelosuppression at stea-
dy-state diaziquone plasma levels of 101 ± 10 ng/mL
(mean ± standard error of mean) during 7-day constant
infusions. In conclusion: (a) hematopoietic cells are more
sensitive than marrow stromal cells to the dose- and highly
time-dependent cytotoxicity of diaziquone. (b) a direct
drug-induced noxious effect on the marrow microenviron-
ment is an unlikely cause of the isolated episodes of
marrow necrosis after the use of diaziquone in vivo, and (c)
prolonged infusion of diaziquone represents an attractive
means for achieving myeloablation in selected clinical situ-
ations.
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were prepared with the medium appropriate for the specific culture
technique being used. When reconstituted in solution maintained at
pH 7.0, diaziquone has a half-life of I 7 days.’5
Marrow buffy coat cells in alpha-medium (Flow Laboratories,
Hamden, CT) with 10% heat-inactivated fetal calf serum (FCS)
were incubated at 5 x lO6cells/mL with graded doses of diaziquone
for I , 3 or 6 hours at 37#{176}Cin a humidified 5% CO2 atmosphere, and
washed three times prior to use. In experiments examining the
effects of prolonged drug exposure, marrow cells were resuspended
and cultured in medium containing diaziquone in the amounts
needed to achieve the desired drug concentration.
Culture Techniques
Multilineage and erythroid colony-forming cells. Mononuclear
cells were recovered from untreated or diaziquone-treated marrow
buffy coat cells by neutral density centrifugation in an isotonic
sterile Percoll solution, 1.074 g/mL, 270 mosm (Pharmacia, Pis-
cataway, NJ). These cells or SBA-E-cells were cultured’6 in quadru-
plicate in 35-mm dishes (Lux Scientific Co. Newburg, CA) at I .0 x
lOt/mL of 1% methylcellulose in Iscove’s modified Dulbecco
medium with 30% human plasma, 10% phytohemagglutinin-stimu-
lated leukocyte-conditioned medium, 5 x l0 mol/L 2-mercapto-
ethanol, and one unit of human recombinant erythropoietin (A MG-
Bone Marrow Cells
Heparinized marrow aspirated from the iliac crests of healthy
volunteers who gave informed, written consent were centrifuged at
200 g for ten minutes. The buffy coat cells were collected and
washed. For some experiments, marrow was fractionated by aggluti-
nation with soybean lectin and by rosetting with sheep erythrocytes
to isolate a target population (SBA-E--cells) enriched for hemato-
poietic cells and 97% to 99+%-depleted of stromal cells’3 and T
cells. ‘
Diaziquone Preparation and Drug Exposure
Diaziquone was provided in 10-mg vials by the National Cancer
Institute. It was reconstituted in N,N-dimethylacetamide and phos-
phate buffer saline immediately before use. Further drug dilutions
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en, Thousand Oaks, CA). CFU-Mix and BFU-E were scored on
day 14.
Granulocyte-macrophage colony-forming cells. Marrow cells
were cultured as described’7 in quadruplicate in 35-mm dishes
(Corning Glass Works, Corning, NY) at 2 x l05/mL of0.3% agar
in supplemented McCoy’s 5A medium and 10% FCS. In each dish,
0. 1 mL of medium conditioned by the 5637 bladder carcinoma cell
line stimulated colony formation.’8 CFU-GM (more than 50 cells!
aggregate) were scored on day 7.
Fibroblast colony-forming cells. Marrow buffy coat cells (5 x
106) in 20 mL alpha-medium with 20% FCS were set up in T-75
flasks (Corning) that were gassed with 5% CO2 in air and kept at
37#{176}C.Medium was changed on day 4 in cultures of cells preincu-
bated with diaziquone for I, 3, or 6 hours. In cultures exposing cells
to diaziquone for three or seven days, the initial medium contained
graded amounts of diaziquone but was replaced by drug-free
medium on day 3 in one set of experiments, and on day 7 in another
set. Cultures were stopped on day 10, stained with Wright-Giemsa
solution, and scored for CFU-F (more than 50 cells/aggregate).’9
Long-term marrow cultures. Marrow buffy coat cells (20 x
106) suspended in 10 mL medium were inoculated into T-25 flasks
(Corning) that were gassed with 5% CO2 in air, and kept at 37#{176}C.
The medium consisted of supplemented McCoy’s 5A medium,’7
12.5% horse serum, 12.5% FCS, and l06 mol/L hydrocortisone
sodium succinate, with or without graded amounts of diaziquone,
depending on the experimental design. On day 3 in one set of
experiments and on day 7 in a separate set, supernatants were
purged of erythrocytes and mature myeloid cells by Percoll separa-
tion; the mononuclear cells were returned to their flasks in fresh,
drug-free medium. LTMCs were then maintained at 33#{176}C.Half of
the supernatant was removed weekly and the cells in suspension were
assayed for CFU-GM. At week 3, adherent layers in some flasks
were suspended’7 using a nontoxic 0.01% (wt/vol) Ca- and
Mg f-free trypsin (GIBCO, Grand Island, NY) solution to deter-
mine their CFU-Mix, BFU-E, and CFU-GM content.
To monitor stromal layer development, the extent of flask cover-
age by an interlocking network of cells was estimated weekly by
phase microscopy. Cellular composition was assessed in situ by
immunofluorescence methods.’7 Fibroblasts were identified by rab-
bit antibodies to fibronectin (Bethesda Research Lab, Gaithersburg,
MD) and to collagen type Ill (Dr H Furthmayr, Yale University).
Endothelial cells and macrophages were identified by mouse mono-
clonal antibodies (Australian Monoclonal Development, Antarmon,
Australia) to factor VlIl-related protein and to human monocytes/
macrophages, respectively. Adipocytes were distinguished by their
morphology.
Statistical Analysis
With the Minitab package program (Duxbury Press, Boston),
regression analyses were performed for the clonogenic assays using
the log of the percent of the control as the dependent variable and the
diaziquone dose as the independent variable. Lines were forced
through the value of the log of I 00% at dose zero. Slopes of the fitted
lines were compared based on F-tests computed from residual sums
of squares.
RESULTS
Effect ofDiaziquone on Marrow Colony-Forming Cells
Diaziquone exerted dose- and time-dependent killing of
clonogenic hematopoietic and stromal cells (Fig I). One-
hour treatments did not significantly affect recovery of these
Fig 1 . Survival curves of marrow hematopoietic and stromal
progenitors. Results shown are the mean (SEM less than ± i 0%) of
three (CFU-Mix. BFU-E) and four (CFU-GM. CFU-F) experiments
at each exposure time. Controls were: CFU-Mix. 1 9 ± 2 per 4 x
10 cells; BFU-E. 94 ± 9 per 2 x 10 cells; CFU-GM. 91 ± 7 per i0
cells; and CFU-F, 1 31 ± 1 5 per 5 x 1 0 cells. Note the marked
time-dependency of diaziquone cytotoxicity on all four cell types.
cells, even at high drug concentrations (500 to 5,000 ng/mL,
data not shown). With longer treatments, increasing doses
caused an exponential decrease in progenitor recovery.
Three-hour treatments with I ,000 ng/mL produced approxi-
mately 30% reductions in CFU-Mix, BFU-E, and CFU-.
GM survival, and 10% to 15% decrease in CFU-F. With
6-hour treatments, doses that inhibited 50% (ID) of CFU-
Mix, BFU-E, and CFU-GM were 160 ng/mL, 200 ng/mL,
and 245 ng/mL, respectively, which were significantly lower
than the ID50 of 530 ng/mL for CFU-F (P = .001).
CFU-Mix and BFU-E did not differ significantly in sensi-
tivity to diaziquone ( P = . 15), but these progenitors were
significantly more sensitive than CFU-GM (P = .005).
After 6-hour exposure to 5,000 ng/mL, hematopoietic pro-
genitors were not detected, but CFU-F recovery was 10%.
When marrow buffy coat cells were plated with graded
amounts of diaziquone in the culture medium, ie, 7-day
constant exposure, the ID50 of CFU-GM formation was 60
ng/mL, and CFU-GM recovery was 5% at 250 ng/mL (Fig
I ). To ascertain whether this inhibition was a direct effect on
hematopoietic cells or was mediated via effects on accessory
“helper” cells, SBA-E-cells were cultured under the same
constant-exposure conditions. Survival curves of CFU-GM
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matched those observed using buffy coat cells (data not
shown).
When marrow buffy coat cells were cultured for CFU-F
with graded amounts of diaziquone in the medium for seven
days, ie, 7-day constant exposure, the ID50 of CFU-F was
I 10 ng/mL (Fig 1). Similar results-CFU-F ID50 of 145
ng/mL-were obtained with 3-day constant exposures (data
not shown).
Effect ofDia:iquone on LTMCs
Diaziquone dosage and length of treatment significantly
affected LTMCs regarding CFU-GM production, the rate
of development, and the cellular composition of adherent
layers. Marrow suspensions treated for one or three hours
(Fig 2) with doses ofdiaziquone up to 5,000 ng/mL and then
set up in LTMCs produced CFU-GM for five to six weeks
and gave rise to adherent stromal layers that, similar to
controls, reached confluence within three to four weeks and
contained fibroblasts, macrophages, adipocytes, and rare
endothelial cells (Table I).
Treatments for six hours (Fig 3) caused more marked
dose-dependent reductions in CFU-GM yields. In particu-
lar, following 6-hour treatments with very high doses of
diaziquone, eg, 5,000 ng/mL, marrow suspensions that were
depleted ofCFU-Mix, BFU-E, and CFU-GM, as measured
by direct assay in semisolid medium, generated CFU-GM
for five weeks in LTMCs. Six-hour treatments with diazi-
quone up to 500 ng/mL did not adversely affect stromal
layer development or composition (Table I ) as compared to
controls; at 1,000 ng/mL, however, confluence was very
delayed, and at 5,000 ng/mL confluence was not attained.
LTMCs exposed to diaziquone for three or seven days (Fig
4) at doses up to 100 ng/mL generated CFU-GM for five or
more weeks. Doses of I 50 ng/mL or greater abolished
recovery of CFU-GM from either the nonadherent or the
3-week-old adherent cellular compartments of LTMCs. Pro-
longed exposure to doses of diaziquone up to 250 ng/mL
retarded the development ofconfluent stromal layers but did
not alter the heterogeneous cellular composition as compared
to untreated controls (Table I ). After prolonged exposures to




















adipocytes were identified. Higher doses resulted in occa-
sional-to-rare fibroblastic areas.
DISCUSSION
Our studies demonstrate differential sensitivities to diazi-
quone of hematopoietic as compared to marrow stromal cells,
highlight the time-dependency of diaziquone’s cytotoxic
activity, and support using prolonged, myeloablative infu-
sions of diaziquone in conjunction with bone marrow trans-
plantation.
One- and three-hour treatments with up to 5,000 ng/mL
diaziquone had little effect on hematopoietic progenitors,
whereas 7-day exposure to doses as low as 50 ng/mL had a
significant cytotoxic impact on these cells. Data from CFU-
Mix, BFU-E, and CFU-GM, however, may not apply to the
pluripotent stem cell that constitutes the target of definitive
myeloablative procedures prior to bone marrrow transplan-
tation. Differences in drug effects on committed versus
pluripotent hematopoietic cells are inferred from the in vivo
hematologic regenerative capacity of harvested marrow
depleted of CFU-Mix, BFU-E, and CFU-GM by purging
with 4-hydroperoxycyclophosphamide (4-HC).20’2’ Direct
measurement of the pluripotent stem cell is not now feasible
in humans, but LTMCs may provide an indirect means for
detecting hematopoietic cells that are more primitive than
CFU-Mix. We observed sustained production of CFU-GM
in LTMCs initiated with marrow completely depleted of
CFU-Mix, BFU-E, and CFU-GM by 6-hour treatments
with 5,000 ng/mL diaziquone. These findings, similar to
results with anti-Ia antibody,22 4-HC,2’ and VP-16,24’25 mdi-
cate an ongoing input of CFU-GM from a surviving, pre-
CFU-Mix population. In sharp contrast, CFU-GM were not
recovered from LTMCs following three- or seven-day expo-
sures to I 50 ng/mL diaziquone. These data support an
ablative effect on pre-CFU-Mix of prolonged exposure to
low doses of this drug.
Although eliminated from LTMCs exposed for three to
seven days to 150 ng/mL diaziquone, CFU-GM are detect-
able at seven days when marrow is cultured in semisolid
medium containing doses up to 250 ng/mL. These seemingly
inconsistent findings are not attributable to diaziquone
Fig 2. Effects of 3-hour treatments with diaziquone on LTMC stromal layer development (left) and CFU-GM generation (right). Note
the relatively minor differences in these parameters over a wide range of diaziquone dosages. Results shown are the mean of three
experiments.
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Table 1 . Corn position of Strom al Layers in LTM Cs Der ived Fr om Diaziquone-T reated Bone Marrow
Length
Expostte
250 ng/mL 500 ng/mL 1 .000 ng/mL 5.000 ng/mL
F M Ad EC F M Ad EC F M Ad EC F M Ad EC
3hr 4+ 2+ 3+ 1+ 4+ 2+ 3+ 1+ 4+ 2+ 3+ 1+ 3-4+ 1-2+ 2+ ±
6hr 4+ 2+ 3+ 1+ 4+ 2+ 3+ 1+ 4+ 1+ 1-2+ 0 2-3+ 0 1+ 0
3days 4+ 2+ 3+ 0-1+ 2-3+ 0 1-2+ 0 1+ 0 0 0 0-1+ 0 0 0
The presence and relative amount of different types of adherent stromal cells was semiquantitatively assessed. Control stromal layers derived from
20 x 106 untreated marrow buffy coat cells exhibited the following composition: F, 4 + ; M, 2 + ; A. 3 + ; EC. ± - 1 +.
F. fibroblast; M, macrophage; Ad, adipocyte; EC. endothelial cell.
effects on accessory cells, since CFU-GM survival curves
using buffy-coat cells or stromal-cell- and T-cell.-depleted
SBA-E-marrow fractions overlap. Diaziquone’s cellular
kinetics provide a more convincing explanation. Slow cellular
uptake’8 rather than cell-cycle-specificity26 accounts for the
ti me-dependency of diaziquone’s cytotoxicity. When marrow
is assayed for CFU-GM by direct plating in semisolid
medium containing diaziquone (ie, constant 7-day drug
exposure) progeny-appearing as colonies of cells-are gen-
erated before sufficient drug is accumulated to produce a
cytotoxic effect on the progenitor cell. In contrast, when the
effects of prolonged drug exposure are studied using
LTMCs, drug uptake proceeds for several days, reaching
cytotoxic intracellular levels, before hematopoietic progeni-
tor cell assays are performed. In assessing the cytotoxicity of
prolonged diaziquone exposure, therefore, we view the
LTMC data as more reflective of the in vivo situation than
the data from semisolid medium assays. In fact, the hemato-
poietic-stem-cell ablative diaziquone regimen defined in our
system-3-day exposure to 1 50 ng/mL-correlates with
cli nical experience6: prolonged but reversible myelosuppres-
sion followed seven-day constant infusions ofdiaziquone that
produced steady-state plasma concentrations of 101 ± 10
ng/mL (mean ± SEM; range 54-150 ng/ml). Presumably,
higher drug levels (as in our system) cause myelosuppression
that is unacceptable in the absence of bone marrow rescue.
Bone marrow necrosis in two of three patients treated by
prolonged infusions of maximal doses of diaziquone6 raises
the issue of drug-induced damage to the marrow microenvi-
ronments.’2 Such an effect might block hematologic recovery
posttransplantation of bone marrow and would make this





















plant use. Our in vitro hematopoietic-stem-ceIl ablative
diaziquone regimen is relatively sparing of marrow stromal
progenitors, as shown by the 40% recovery of CFU-F.
Moreover, adherent layers that formed in LTMCs after
prolonged treatments with up to 250 ng/mL of diaziquone
attained confluence and resembled untreated controls
regarding heterogeneity of cellular composition. We inter-
pret these data as supporting the analysis6 that other factors,
eg, vessel occlusion secondary to rapid and extensive cell lysis
within a markedly hypercellular marrow,” caused the necro-
sis. Additional support for this view comes from radiation
data. In vitro radiation at 480 to 840 cGy (depending on the
dose rate) abolishes human CFU-F recovery and inhibits
LTMC stromal layer development,28’29 yet patients irra-
diated with up to 1,440 cGy routinely engraft with bone
marrow transplants,’#{176} indicating an intact marrow microen-
vironment. It may be deduced that since (relative to their
respective myeloablative dosages) diaziquone is much less
toxic in vitro than radiation to marrow stromal cells, a
similar situation prevails in vivo.
Total body irradiation and busulfan, the conventional
methods of myeloablation prior to bone marrow transplanta-
tion, have overlapping pulmonary toxicities3’ that make it
risky to use both modalities in the same patient within a short
period of time. Yet, repeat or intensified myeloablative
measures may be indicated (a) to prepare patients for a
second transplant,” (b) to treat refractory acute leuke-
mias, or (c) to ablate the expanded, abnormal primitive-
stem-cell compartments of disorders such as juvenile chronic
myeloid leukemia (JCML) or blastic-phase chronic
myelogenous leukemia (Ph’+ CML).’4’6 Intensive diazi-
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Fig 3. Effects of 6-hour treatments with diaziquone on LTMC strornal layer development (left) and CFU-.GM generation (right). Results
shown are the mean of three experiments. Note the prolonged generation of CFU-GM in LTMCs derived from marrow suspensions that at
the time of LTMC initiation were depleted by treatments with 5.000 ng/mL of directly measurable hematopoietic progenitors.
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Fig 4. Effects of 3-day exposures to diaziquone on LTMC stromal layer development (left) and CFU-GM generation (right). Results
shown are the mean of four experiments and are similar to those obtained with 7-day treatments. Note that prolonged treatment with 150
ng/mL abolishes CFU-GM generation but does not impair stromal layer development.
injections45 or by constant infusion6-are effective in clear-
ing blasts from patients with refractory or relapsed acute
nonlymphocytic leukemias and from patients with panmyel-
opathies such as JCML, Ph’+ CML, and secondary leuke-
mia. These results have been clouded, however, by prolonged,
life-threatening aplasia. No significant extramedullary tox-
icity, pulmonary in particular, has been seen at doses used
thus far.6’7 Our data indicate that a diaziquone regimen
adjusted to maintain plasma levels of approximately ISO
ng/mL for three to seven days is myeloablative without
undue toxicity to the marrow microenvironment. Taken
together, these clinical and laboratory findings favor incor-
poration into transplant preparative protocols of this rela-
tively nontoxic approach when, as in the clinical situations
listed above, repeat or highly aggressive myelotoxic measures
are desired. Since other studies demonstrate that prolonged
exposure to suprapharmacologic doses of diaziquone does not
significantly suppress lymphocyte mitogenic responses sig-
nificantly (Chin Li, Kushner BH, Cunningham-Rundles S.
Castro-Malaspina H: unpublished data), the use of diazi-
quone in the allogeneic marrow transplant setting must be
coupled with immunosuppressive measures.
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